AAV Tropism for Kidney Tissues

The kidney is considered one of the most challenging organs for AAV gene therapy due to the physical barriers of the renal filtration system and the complexity of its specialized cell types (podocytes, tubular epithelial cells, and mesangial cells).

While natural serotypes like AAV2 and AAV9 show some affinity, researchers are increasingly turning to synthetic “designer” capsids to achieve meaningful therapeutic levels.

Serotype	Target Tissue/Cells	Transduction Efficiency	Best Use Case	Notes
AAV2	Tubular Epithelium	Moderate	Local renal delivery	One of the first studied for the kidney; targets the cortex well but has limited spread.
AAV9	Podocytes / Tubules	Moderate	Systemic delivery	Best natural serotype for crossing into the kidney from the blood, especially in diseased (CKD) states.
AAV8	Tubular Epithelium	Low/Moderate	Local injection	Effective when injected directly into the renal parenchyma, but poor via IV.
AAV6.2	Tubular Epithelium	High	Direct renal injection	A natural variant that often outperforms AAV8 and AAV2 in direct kidney injections.
AAV-LK03	Human Podocytes	Very High	Genetic kidney disease	A synthetic capsid that excels at transducing human podocytes, outperforming most natural strains.
AAV-KP1	Proximal Tubules	Ultra High	Localized therapy	Synthetic; specifically engineered for the kidney. Shows 10-100x better efficiency than AAV9 with lower liver “leakage.”
AAV2-GEC	Glomerular Endothelial	High	Inflammatory disease	Synthetic; recently developed to specifically target the “filters” of the kidney (endothelial cells).
Anc80	Mesenchymal Cells	High	Fibrosis research	An evolutionarily “ancestral” synthetic AAV that targets kidney fibroblasts and mesenchyme effectively.

Overcoming the “Filtration Barrier”

The main reason natural AAVs struggle with the kidney is that the body is designed to filter out particles of that size. To get around this, researchers use specific Routes of Administration:

1. Intravenous (IV): Simple but inefficient. Most virus is caught by the liver before it reaches the kidney. AAV9 is the most common choice here, particularly for Chronic Kidney Disease (CKD) models where the barrier is “leaky.”
2. Renal Artery/Vein Infusion: Directly “flooding” the kidney with the virus. This bypasses the liver and allows serotypes like AAV-KP1 to work at much lower doses.
3. Retrograde Ureteral Injection: Injecting the virus “backward” up the ureter. This is excellent for targeting the collecting ducts and tubular epithelium without systemic exposure.

Kidney-Specific Promoters

To ensure the therapy doesn’t cause side effects in other organs, the following promoters are used to restrict gene expression:

• NPHS1 / NPHS2 (Podocin): Restricts expression strictly to the Podocytes (the filtering cells).
• Ksp-Cadherin: Targets the Renal Tubules.
• Six2: Used in research to target Nephron Progenitor Cells.

A Note on Toxicity

Recent 2025 research using kidney organoids has suggested that high doses of AAV2 can sometimes trigger inflammatory responses in kidney tissue. For this reason, many labs are shifting toward lower doses of more potent synthetic variants like KP1 or LK03.